SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, apparently news-free price spike is driving attention, with traders reacting to an unusually large candle and rapid swings. Some are buying the dip and calling for a rebound, while skeptics see another pump-and-dump and expect gains to fade; several also point to Bitcoin and broader crypto-market moves as context.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Positive Phase III HARMONi-GI1 biliary cancer survival results presented at ESMO are driving attention, with bullish traders viewing them as further evidence for ivonescimab. Others caution that the interim data came from a China-only study and point to the separate November 14 FDA decision for lung cancer as the more consequential near-term catalyst.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Natera is drawing attention after a sustained run to fresh highs, with traders pointing to growth in genetic testing and oncology MRD testing, clinical data, and a reported FDA breakthrough-device designation as support for the bullish narrative. Others say the stock looks overbought or richly valued and are watching for profit-taking or a pullback.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp selloff and volatile, underperforming price action are prompting questions about what drove the drop, with some traders buying the dip while others warn of further downside. The broader debate pits optimism around Compounds institutional and V4 plans and limited token supply against frustration that COMP has lagged other crypto assets.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Cantons institutional adoption and real-world-asset tokenization are driving attention, with traders highlighting DTCCs planned tokenization activity and additions such as Visa as a Super Validator. Optimism about the networks prospects is tempered by debate over CCs muted price performance, token emissions and unlocks, and whether network usage will translate into value for holders.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

A sharp QNT rebound has fueled breakout and short-squeeze chatter, with traders tying the move to Quants Clearing House On-Chain Money Initiative and prospects for tokenized bank deposits. Bulls see institutional adoption and limited supply as potential tailwinds, while skeptics question whether the software partnership will create direct demand for QNT tokens.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas rally is being tied to expectations that AI agents and rising cyber risks will boost demand for identity security, alongside broader strength in cybersecurity stocks. Traders are celebrating the breakout and analyst optimism, while skeptics argue the valuation has outrun modest growth and that AI-related revenue remains early.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins pullback is driving discussion, with many traders calling it a temporary dip and buying or holding for a recovery, while others warn of further downside and consider selling or puts. The debate reflects Bitcoins recent volatility and reported outflows from spot ETFs.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Takeover interest and activist pressure to sell Mattel are dominating discussion, with traders debating whether a buyer or bidding contest could emerge. The community is split between seeing a sale as a catalyst and cautioning that talks remain uncertain and no deal is assured.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for range-bound, choppy trading, with repeated technical-chart commentary describing consolidation and traders watching for a breakout. Some holders are accumulating and anticipating a meme-coin rally, while others are frustrated by the lack of sustained momentum and question the tokens utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot

Equity

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy


Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio...

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...

Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Allogene Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Citizens downgraded Cellectis to ‘Market Perform’ from ‘Outperform’ without a price target.</li><li>Cellectis is stopping the development of Lasme-cel and Eti-cel, two allogeneic CAR-T treatments being studied for blood cancers.</li><li>The company will continue existing cell-therapy partnerships with AstraZeneca, Allogene Therapeutics, Servier and Iovance Biotherapeutics</li></ul>Cellectis (CLLS) remained on investors’ radar on Tuesday as the biotech firm received a downgrade from Citizens after it stopped further development of its lead blood-cancer treatments and shifted its focus toward cardiovascular diseases.Citizens downgraded Cellectis to ‘Market Perform’ from ‘Outperform’ without a price target. The firm said the strategy change pushes the company’s major clinical catalysts out to late 2027 and 2028, and it now views the shares as fairly valued.<a href="https://stocktwits.com/symbol/CLLS">CLLS shares</a> were down more than 14% in pre-market trading and are on track to slump to their lowest levels since July 2025. CLLS stock crashed more than 40% in the previous session.<h2 class="st-heading-2">Why Is Cellectis Pivoting?</h2>Cellectis is stopping the development of Lasme-cel and Eti-cel, two allogeneic CAR-T treatments being studied for blood cancers. Allogeneic CAR-T treatments use immune cells from healthy donors that are genetically modified to attack cancer.The company said improvements in existing cancer treatments have reduced the number of patients reaching later stages of therapy, while growing competition from bispecific antibodies and newer in-vivo CAR-T approaches has made the market less attractive.Cellectis will instead focus on using its gene-editing technology directly inside a patient’s body, initially targeting cardiovascular risk factors.<h2 class="st-heading-2">No Changes To Existing Partnerships With AZN, ALLO, IOVA</h2>Cellectis said the restructuring should extend its cash runway into the second half of 2028. It will also continue existing cell-therapy partnerships with&nbsp;<a href="https://stocktwits.com/symbol/AZN">AstraZeneca (AZN)</a>, Allogene Therapeutics, Servier and&nbsp;<a href="https://stocktwits.com/symbol/IOVA">Iovance Biotherapeutics (IOVA)</a>.The company’s lead program, HEAL-101, is designed to lower very high levels of triglycerides, a type of fat in the blood that can increase the risk of heart disease and other serious health problems. Early Phase 1 data are expected in the second half of 2027.Its second program, HEAL-201, is designed to lower lipoprotein cholesterol, or ‘bad’ cholesterol, which can contribute to heart disease. Early Phase 1 results are expected in the first half of 2028.<h2 class="st-heading-2">Retail ‘Extremely Bullish’ Despite Sharp Selloff</h2>Despite the massive sell-off, retail sentiment surrounding CLLS on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours.CLLS shares have crashed more than 62% so far this year, underperforming partner IOVA’s 267% surge,&nbsp;<a href="https://stocktwits.com/symbol/ALLO">ALLO’s</a> 31% gains and AZN’s 10% losses.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/ai-fed-5-treasury-yield-three-risks-putting-nasdaq-dow-futures-on-edge-ahead-of-wednesday-rate-decision/cZtnPK2RBTu">&nbsp;AI, Fed And 5% Treasury Yield: Three Risks Putting Nasdaq, Dow Futures On Edge Ahead Of Wednesday’s Rate Decision</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Cellectis logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy

CLLS Stock Slides Toward 14-Month Low: Citizens Downgrades Cellectis After Cancer Pipeline Pivot 

AstraZeneca PLC

Cellectis

Iovance Biotherapeutics Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.25
Prev Close	$1.25
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$1.70
Beta	1.73
Avg. Volume	5.79M
PE Ratio	-1.88

52-Week High	$4.46
52-Week Low	$1.04
Market Capitalization	$431.86M
EPS (Annual)	-$0.8652
Price to Book	0.99
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALLO Fundamentals